Company Data

• Development, licensing and sales of controlled breathing technologies for the delivery of inhaled therapeutics.

• 1998
  Spin-out from the GSF (Research Center for Environment and Health) under the name of Inamed GmbH.

• 2004
  The CRO and devices business were split and Activaero became a stand alone company in 2005.

• Gemünden/Wohra near Frankfurt, Germany

• Gauting near Munich, Germany

• Dublin, Ohio, USA

• 42

• AKITA^® JET Inhalation System [more]

• AKITA² APIXNEB^TM Inhalation System [more]

• LimiX Flow-Limitation Valve [more]

• Comprehensive IP Portfolio

• Aerosol Science

• Device Development

• Clinical Project Management

• Regulatory, Quality and Clinical Consulting

• Manufacturing & Logistics

• Marketing & Sales

• Performed > 30 clinical trials  with AKITA^® inhalation systems in Europe, USA and other territories.

• Aerosol in vitro characterization for more than 30 various molecules, small size (e.g. Glutathione) proteins and big molecules (e.g. Pneumococcal Vaccine).

• 7 scintigraphic studies performed with AKITA^® inhalation systems (best device worldwide with regard to lung/regional deposition).

• At present time 10 ongoing investigations/trials with approximately 500 patients using AKITA^® devices.

• A number of 15 clinical trials successfully performed with the AKITA² APIXNEB system.With the previous AKITA^® system, 23 clinical trials successfully performed.

• Dr. Gerhard Scheuch, Founder and CEO

• Axel Fischer, Managing Director and COO

• Bernhard Müllinger, CTO

• Christian M. Pangratz, CBO

• Dr. Thomas Hofmann, CMO

• William C. Zimlich, CEO, Activaero  America, Inc.

• Dr. Stefan Degenhardt, CFO

• Dr. Florian Fischer, Corporate Development

• Abalis Finance AG

• BioMedInvest II LLP

• Venture Incubator AG Vesalius

• BioCapital S.A. SICAR

• Cathay World Investments Limited

Activaero closed a 10.7 million Euro series A round in 2009.

• Dr. John Patton

• Dr. Jean-Marie Luechinger

• Dr. Gerhard Ries

• Dr. Arnd Kaltofen-Ehmann

• Dr. Christian Schneider

• Erasmus Medical Center, Rotterdam
  
  
• Harvard Medical School
  
  
• Universitätsklinikum Gießen und Marburg (UKGM)
  
  
• Helmholtz Zentrum München

• Grifols - inhaled AAT for hereditary emphysema

• Bayer HealthCare - undisclosed

• Ablynx - undisclosed

• Several undisclosed partnerships for early clinical trials with biopharmaceutical companies.

• 1998
  Foundation of Inamed GmbH as a spin-off from the GSF (today, the Helmholtz Center München) in Gauting.

• 2001
  Center for logistics and administration opens in Gemünden.

• 2003
  Exclusive licensing agreement with Talecris Biotherapeutics for the development of inhaled Alpha-1-Antitrypsin for the treatment of emphysema.

• 2004
  The CRO (Inamed) and devices division (Activaero) split into separate companie.

• 2007
  Foundation of Activaero America, Inc.

• 2008
  Licensing agreement with Bayer HealthCare GmbH for the development of inhalation therapie.

• 2009
  Close of a 10.7 million Euro Series A financing round extension and further development of the headquarters in Gemuenden.
  Construction of a separate branch for clinical research.

• 2002
  Market launch of the first AKITA^® inhalation system.

• 2006
  Marktet launch of the AKITA² inhalation system for clinical studies and pharma partnerin.

• 2007
  USA market approval for AKITA² APIXNEB^TM inhalation system and market launch of the Watchhaler spacer for children.

• 2008  
  USA market approval for Watchhaler spacer.

• 2009  
  Market launch of the AKITA^® JET inhalation system and USA market approval for  the AKITA^® JET inhalation system.

• 2005
  Inamed ranks as one of the TOP 100 most innovative companies in Germany.

• 2006
  AKITA² APIXNEB^TM inhalation system receives the reddot design award.

• 2009
  Activaero wins under the category "Market and Customer" at the F.A.Z. Institute's STEP Awards and was finalist in the corporate "Hessen Champions" competition.

• 2010
  Activaero wins in the corporate "Hessen Champions" competition